Abstract
The surface antigen of hepatitis B virus (HBsAg) spontaneously aggregates into ‘empty’ virus-like particles (VLPs) in the absence of other viral components. The powerful immunogenicity of HBsAg when administered either as VLPs or as naked DNA invites its exploitation as a vector for the delivery of antigenic determinants from other organisms. Here we discuss ways in which HBsAg may be modified to derive vaccines against disease-related pathogens. We review studies demonstrating the induction of disease-protective antibody and T-cell responses induced by immunization with recombinant HBsAg vaccines, and consider how these vaccines might best be delivered. Unmodified HBsAg VLPs are licensed for use in humans as the pan-global vaccine to prevent hepatitis B virus infection, suggesting that route-tomarket for recombinant HBsAg vaccines might be simplified.
Keywords: Hepatitis B surface antigen, vaccine, DNA, virus-like particle, cytotoxic T-cell, antibody
Current Drug Therapy
Title: Genetically Modified Hepatitis B Surface Antigen: A Powerful Vaccine Technology for the Delivery of Disease-Associated Foreign Antigens
Volume: 3 Issue: 3
Author(s): Scott Thomson, Oscar Haigh, Allan Gould and Robert Tindle
Affiliation:
Keywords: Hepatitis B surface antigen, vaccine, DNA, virus-like particle, cytotoxic T-cell, antibody
Abstract: The surface antigen of hepatitis B virus (HBsAg) spontaneously aggregates into ‘empty’ virus-like particles (VLPs) in the absence of other viral components. The powerful immunogenicity of HBsAg when administered either as VLPs or as naked DNA invites its exploitation as a vector for the delivery of antigenic determinants from other organisms. Here we discuss ways in which HBsAg may be modified to derive vaccines against disease-related pathogens. We review studies demonstrating the induction of disease-protective antibody and T-cell responses induced by immunization with recombinant HBsAg vaccines, and consider how these vaccines might best be delivered. Unmodified HBsAg VLPs are licensed for use in humans as the pan-global vaccine to prevent hepatitis B virus infection, suggesting that route-tomarket for recombinant HBsAg vaccines might be simplified.
Export Options
About this article
Cite this article as:
Thomson Scott, Haigh Oscar, Gould Allan and Tindle Robert, Genetically Modified Hepatitis B Surface Antigen: A Powerful Vaccine Technology for the Delivery of Disease-Associated Foreign Antigens, Current Drug Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157488508785747844
DOI https://dx.doi.org/10.2174/157488508785747844 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Effect of Monoamine Oxidase Inhibition on Rewarding Effects of Nicotine in Rodents
Current Drug Abuse Reviews Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design New, Substituted Derivatives of Dicarboximides and their Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry CC and CXC Chemokines in Breastmilk are Associated with Mother-to- Child HIV-1 Transmission
Current HIV Research The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Multifunctionalized Microbubbles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Structure-Based Docking Studies of GLUT4 Towards Exploring Selected Phytochemicals from Solanum xanthocarpum as a Therapeutic Target for the Treatment of Cancer
Current Drug Discovery Technologies